In an era where technology continuously redefines healthcare, NeuraSim Pvt Ltd is at the forefront of this transformation. Founded by Dr. Ramesh S Ve, NeuraSim is pioneering immersive digital therapeutics with its flagship product, BeeVee™, aimed at revolutionizing the treatment of amblyopia. Traditional methods like eye patching have long been the standard but come with limitations such as discomfort, high dropout rates, and incomplete recovery. NeuraSim, in collaboration with QWR’s advanced XR hardware, is changing this narrative by leveraging AI and extended reality (XR) to make vision therapy more effective, engaging, and accessible.
In an exclusive interview, Dr. Ramesh S Ve delves into the inspiration behind BeeVee™, the challenges of bringing a digital therapeutic solution to market, the impact of Shark Tank India, and the future of AI-driven healthcare.
Product & Innovation
What inspired you to develop BeeVee™, and how does it address the limitations of traditional amblyopia treatments?
NeuraSim’s journey began with a simple yet powerful question: Why are we treating a modern problem with outdated methods? Amblyopia, a condition affecting millions globally, has traditionally been managed with eye patching—a method that is slow, uncomfortable, and often leads to high dropout rates. “This wasn’t just a medical gap; it was a human problem,” shares Dr. Ramesh. Children with amblyopia often face isolation, and the lack of engaging treatment options only compounds the challenge.
The turning point came when Dr. Ramesh met Avi, now NeuraSim’s CTO, who was also battling amblyopia. With Avi’s background as a VR developer, the idea of integrating immersive therapy with hardware took shape, leading to the creation of BeeVee™. This digital therapeutic solution combines immersive VR experiences with personalized therapy to reprogram neural pathways and restore binocular vision, making treatment more engaging and effective.
Can you walk us through the AI-driven technology behind BeeVee™ and how it enhances patient engagement and recovery?
BeeVee™ is designed to adapt to each patient’s needs through real-time difficulty scaling, ensuring exercises adjust dynamically based on the patient’s performance. The platform leverages neuroplasticity-driven vision correction to reprogram neural pathways, while its remote monitoring and analytics feature allows doctors to track patient progress without frequent in-person visits.
Dr. Ramesh reveals that NeuraSim is taking its AI capabilities even further. “We’re building adaptive AI that personalizes each therapy session in real time,” he explains. In collaboration with QWR, NeuraSim is also developing an eye-tracking XR headset, which will enhance precision and scalability of the therapy.
What were the biggest challenges in developing and clinically validating BeeVee™ as a digital therapeutic solution?
Validating a new category of medical XR therapy came with its set of challenges. NeuraSim needed to conduct rigorous clinical trials and collaborate with leading hospitals to ensure BeeVee™ was safe, effective, and scalable. Additionally, integrating AI-driven therapy with QWR’s XR hardware required deep tech optimization for seamless performance in both clinical and home settings.
Market & Impact
How has BeeVee™ been received by patients, parents, and doctors?
The response has been transformative. Traditional eye patching is often abandoned due to discomfort and slow progress. In contrast, BeeVee™ has demonstrated 3X faster vision improvement, leading to its adoption by over 70 hospitals. “For parents, it’s no longer a daily battle to convince their child to stick with therapy. For doctors, it’s a game-changer,” says Dr. Ramesh. Many ophthalmologists now prescribe XR therapy as the first-line treatment for amblyopia, marking a paradigm shift in vision care.
With amblyopia being a global concern, do you have plans to scale BeeVee™ beyond India?
Absolutely. NeuraSim is actively expanding into Southeast Asia, the Middle East, and North America, where demand for digital therapeutics and AI-driven healthcare solutions is rapidly growing. “To truly compete at a global level, we need to offer a variety of solutions that cater to different medical needs,” Dr. Ramesh explains. NeuraSim’s partnership with QWR allows them to leverage the PLI scheme for full hardware utilization, ensuring affordability and scalability.
How do you plan to ensure affordability and accessibility for families who may not have easy access to VR-based healthcare solutions?
Affordability is at the core of NeuraSim’s mission. By leveraging QWR’s India-made VRone hardware, the company has significantly reduced costs, making BeeVee™ accessible in hospitals, clinics, and even at home. NeuraSim is partnering with ophthalmologists and hospitals to expand accessibility and is set to launch home therapy sessions in the coming months, eliminating financial and geographic barriers to high-quality vision care.
Shark Tank India Experience & Growth Strategy
How has the Shark Tank India experience impacted NeuraSim in terms of awareness, funding, and business growth?
Participating in Shark Tank India gave NeuraSim massive visibility and solidified medical XR as a serious, investable category in healthcare. The exposure accelerated hospital adoption, establishing immersive therapy as the next frontier in digital therapeutics.
Are you exploring partnerships with hospitals, clinics, or vision care specialists to expand BeeVee™’s adoption?
“Yes, strategic collaborations are key to scaling effectively,” confirms Dr. Ramesh. NeuraSim is actively partnering with top ophthalmology centers, vision specialists, and telehealth platforms to make BeeVee™ the gold standard for amblyopia treatment.
Future Vision & Technological Advancements
NeuraSim is also working on AI-driven innovations like Neurametry and NeuroXR. Can you share insights into these upcoming products?
Expanding beyond amblyopia, Neurametry is an AI-powered diagnostic tool for glaucoma and neurodegenerative diseases, while NeuroXR combines EEG and XR for cognitive therapy. These innovations aim to redefine diagnostics and personalized care in ophthalmology.
What role do you see AI and immersive technologies playing in the future of ophthalmology and digital therapeutics?
“AI and XR are rewriting the future of diagnostics and rehabilitation,” Dr. Ramesh envisions. By integrating AI-powered screening and immersive training, NeuraSim is paving the way for early detection and effective treatment of conditions like amblyopia, glaucoma, and cognitive disorders.
Personal & Entrepreneurial Journey
As a founder, what have been the most valuable lessons you’ve learned in building a deep-tech health startup in India?
Building a deep-tech healthcare startup is a long game, requiring clinical validation, regulatory approvals, and ecosystem partnerships. Collaborating with QWR, hospitals, and telehealth platforms has been crucial for scaling globally while ensuring cost-efficiency.
Conclusion: Shaping the Future of Vision Care
NeuraSim is not just revolutionizing amblyopia treatment but is reshaping how healthcare is delivered through AI-driven immersive therapies. With a bold vision to expand globally and diversify its product range, NeuraSim is on track to redefine digital therapeutics.
Dr. Ramesh S Ve’s journey with NeuraSim reflects a commitment to transforming vision care by making high-quality, immersive healthcare solutions accessible and affordable worldwide. As NeuraSim continues to innovate, it is poised to lead the next frontier in medical XR and AI-driven diagnostics.
